These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24740443)

  • 1. Antiretroviral drug resistance among antiretroviral-naïve and treatment experienced patients infected with HIV in Iran.
    Baesi K; Ravanshad M; Ghanbarisafari M; Saberfar E; Seyedalinaghi S; Volk JE
    J Med Virol; 2014 Jul; 86(7):1093-8. PubMed ID: 24740443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 reverse transcriptase and protease mutations for drug-resistance detection among treatment-experienced and naïve HIV-infected individuals.
    Bokharaei-Salim F; Esghaei M; Khanaliha K; Kalantari S; Marjani A; Fakhim A; Keyvani H
    PLoS One; 2020; 15(3):e0229275. PubMed ID: 32119691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran.
    Memarnejadian A; Menbari S; Mansouri SA; Sadeghi L; Vahabpour R; Aghasadeghi MR; Mostafavi E; Abdi M
    PLoS One; 2015; 10(5):e0126955. PubMed ID: 25962088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012.
    Yang WL; Kouyos R; Scherrer AU; Böni J; Shah C; Yerly S; Klimkait T; Aubert V; Furrer H; Battegay M; Cavassini M; Bernasconi E; Vernazza P; Held L; Ledergerber B; Günthard HF;
    J Infect Dis; 2015 Jul; 212(1):28-38. PubMed ID: 25576600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV Drug Resistance and Phylogeny Profile in Naïve and Antiretroviral-Experienced Patients in Tehran, Iran.
    Farrokhi M; Moallemi S; Baesi K; Ahsani-Nasab S; Gholami M; Sadeghi L; Mohraz M
    Intervirology; 2016; 59(3):131-136. PubMed ID: 27974715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low prevalence of transmitted genetic drug resistance in a cohort of HIV infected naïve patients entering antiretroviral treatment programs at two sites in northern South Africa.
    Nwobegahay J; Selabe G; Ndjeka NO; Manhaeve C; Bessong PO
    J Med Virol; 2012 Dec; 84(12):1839-43. PubMed ID: 23080485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy.
    Sigaloff KC; Kayiwa J; Musiime V; Calis JC; Kaudha E; Mukuye A; Matama C; Nankya I; Nakatudde L; Dekker JT; Hamers RL; Mugyenyi P; Rinke De Wit TF; Kityo C
    AIDS Res Hum Retroviruses; 2013 Jun; 29(6):925-30. PubMed ID: 23517497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries.
    De Luca A; Hamers RL; Schapiro JM
    J Infect Dis; 2013 Jun; 207 Suppl 2():S63-9. PubMed ID: 23687291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study.
    Drescher SM; von Wyl V; Yang WL; Böni J; Yerly S; Shah C; Aubert V; Klimkait T; Taffé P; Furrer H; Battegay M; Ambrosioni J; Cavassini M; Bernasconi E; Vernazza PL; Ledergerber B; Günthard HF; Kouyos RD;
    Clin Infect Dis; 2014 Jan; 58(2):285-94. PubMed ID: 24145874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of an allele-specific PCR to clinical HIV genotyping samples detects additional K103N mutations in both therapy naïve and experienced patients.
    Carr JM; Green T; Shaw D; Daly L; Hart W; Ratcliff R; Higgins G; Burrell CJ; Li P; Qiao M
    J Med Virol; 2009 Dec; 81(12):1983-90. PubMed ID: 19856473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
    Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V
    J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients.
    Edén A; Andersson LM; Andersson O; Flamholc L; Josephson F; Nilsson S; Ormaasen V; Svedhem V; Säll C; Sönnerborg A; Tunbäck P; Gisslén M
    AIDS Res Hum Retroviruses; 2010 May; 26(5):533-40. PubMed ID: 20455766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Frequency of HIV-1 Infection in Iranian Children and Determination of the Transmitted Drug Resistance in Treatment-Naïve Children.
    Jarchi M; Bokharaei-Salim F; Esghaei M; Kiani SJ; Jahanbakhsh F; Monavari SH; Ataei-Pirkooh A; Marjani A; Keyvani H
    Curr HIV Res; 2019; 17(6):397-407. PubMed ID: 31702525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.
    Escoto-Delgadillo M; Vázquez-Valls E; Ramírez-Rodríguez M; Corona-Nakamura A; Amaya-Tapia G; Quintero-Pérez N; Panduro-Cerda A; Torres-Mendoza BM
    HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of HIV drug resistance in antiretroviral therapy-naive and -experienced patients from Papua New Guinea.
    Gare J; Ryan CE; David M; Timbi D; Kaima P; Kombati Z; Imara U; Kelly-Hanku A; Siba PM; Crowe SM; Hearps AC
    J Antimicrob Chemother; 2014 Aug; 69(8):2183-6. PubMed ID: 24722838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon.
    Ceccarelli L; Salpini R; Moudourou S; Cento V; Santoro MM; Fokam J; Takou D; Nanfack A; Dori L; Torimiro J; Sarmati L; Andreoni M; Perno CF; Colizzi V; Cappelli G
    J Med Virol; 2012 May; 84(5):721-7. PubMed ID: 22431019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for antiretroviral drug resistance among treatment-naive human immunodeficiency virus type 1-infected individuals in Lebanon.
    Mokhbat JM; Melhem NM; El-Khatib Z; Zalloua P
    J Infect Dev Ctries; 2014 Mar; 8(3):339-48. PubMed ID: 24619266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.
    Recsky MA; Brumme ZL; Chan KJ; Wynhoven B; Yip B; Dong WW; Heath KV; Montaner JS; Levy AR; Hogg RS; Harrigan PR
    J Infect Dis; 2004 Jul; 190(2):285-92. PubMed ID: 15216463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.